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Abstract 25
In the United States, 1-2.5% of pregnant women are infected with hepatitis C virus (HCV), 26 which carries an approximately 5% risk of transmission from mother to infant. HCV can be 27 transmitted to the infant in utero or during the peripartum period, and infection during pregnancy 28 is associated with increased risk of adverse fetal outcomes, including fetal growth restriction and 29 low birth weight. The purpose of this document is to discuss the current evidence regarding HCV 30 in pregnancy and to provide recommendations on screening, treatment, and management of this 31 disease during pregnancy. The following are Society for Maternal-Fetal Medicine 32 recommendations: (1) we recommend that obstetric care providers screen women who are at 33 increased risk for HCV by testing for anti-HCV antibodies at their first prenatal visit. If initial 34 results are negative, HCV screening should be repeated later in pregnancy in women with 35 persistent or new risk factors for HCV infection after their initial screening (e.g., new or ongoing 36 use of injected or intranasal illicit drugs) (GRADE 1B); (2) we recommend that obstetric care 37 providers screen HCV-positive pregnant women for other sexually transmitted diseases, 38 including human immunodeficiency virus (HIV), syphilis, gonorrhea, chlamydia, and hepatitis B 39 virus (HBV) (GRADE 1B); (3) we suggest that patients with HCV, including pregnant women, 40 be counseled to abstain from alcohol (Best Practice); (4) we recommend that direct-acting 41 antiviral medications (DAA) regimens only be used in the setting of a clinical trial or antiviral 42 treatment should be deferred to the postpartum period as DAA regimens are not currently 43 approved for use in pregnancy (GRADE 1C); (5) we suggest that if invasive prenatal diagnostic 44 testing is requested, women be counseled that data on the risk of vertical transmission isM A N U S C R I P T
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lack of data on the latter (GRADE 2C); (6) we recommend against cesarean delivery solely for 47 the indication of HCV (GRADE 1B); (7) we recommend that obstetric care providers avoid 48 internal fetal monitoring, prolonged rupture of membranes, and episiotomy in managing labor in 49 HCV-positive women (GRADE 1B); (8) we recommend against discouraging breastfeeding 50 based on a positive HCV infection status (GRADE 1A). 51 M A N U S C R I P T
Introduction 72
Worldwide, up to 8% of pregnant women are infected with hepatitis C virus (HCV) (1). In the 73
United States, the estimated prevalence of antenatal HCV infection is 1-2.5%; some studies 74 estimate the prevalence to be as high as 4% (2). The primary mode of HCV transmission is 75 percutaneous exposure to blood from injection of illicit drugs. Other modes of transmission 76 include vertical transmission (mother-to-child), sharing of contaminated devices for non-77 injection drug use, exposure to infected blood through occupational and other means, and, 78 although inefficient, sexual intercourse (3). 79
Two primary concerns arise from HCV in pregnancy: 1) maternal well-being, i.e., the 80 effect of pregnancy on the course of chronic HCV infection, and 2) fetal well-being, namely 81 mother-to-infant transmission of HCV and the impact of maternal infection on pregnancy 82 outcomes. 83
84
EPIDEMIOLOGY 85 86
What is the natural course of HCV infection? 87
HCV can cause both acute and chronic hepatitis. The first 6 months after exposure to HCV is 88 referred to as acute HCV infection. Acute HCV infection is asymptomatic in 75% of cases; when 89 symptoms occur, they include abdominal pain, nausea, anorexia, jaundice, or malaise (4). cirrhosis who are treated with antiviral medications and achieve a sustained virological response, 99 only 5% develop HCC within 10 years. HCC is a primary cause of mortality from HCV infection 100 (7), with a median length of survival after diagnosis of 20 months (8). 101
102
What is the impact of pregnancy on chronic hepatitis C? 103
Serum levels of alanine aminotransferase (ALT) tend to decrease during the second and third 104 trimesters in pregnancies complicated by HCV infection and then return to pre-pregnancy levels 105 after delivery (9-12). In contrast, serum levels of HCV RNA may increase in infected women 106 during the second and third trimesters of pregnancy. One study showed a statistically significant 107 increase in HCV RNA (10) , whereas in another study, this trend was not statistically significant 108 (12). Researchers speculate that the increase in HCV RNA levels during pregnancy is due to 109 down-regulation of the maternal immune response. Because hepatocellular damage caused by 110 chronic HCV infection is thought to be immune-mediated rather than directly caused by viral 111 cytotoxicity, down-regulation of the maternal immune response in pregnancy would be predicted 112 to reduce the amount of hepatocellular damage caused by HCV, which would also account for 113 the decrease in ALT levels. (10) . 114 M A N U S C R I P T
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progression of fibrosis, as determined by liver biopsy, in a retrospective cohort study of 157 117 pregnant women with chronic HCV infection. Specifically, they found that a history of 118 pregnancy was independently associated with a lower likelihood of fibrosis progression (13). In 119 contrast, a small case-control study by Fontaine et al showed worsening of histopathological 120 measures after pregnancy. They compared liver biopsy samples from 12 HCV-positive women 121 obtained before and after delivery, with samples from 12 nonpregnant HCV-positive women as 122 controls. The mean period between initial and final biopsies was 4 years; during this time, 83% 123 of pregnant patients showed deterioration in their necro-inflammatory score, and 42% showed 124 deterioration in their fibrosis score. In comparison, the rates for controls were 25% and 8%, 125 respectively (14). These conflicting data highlight a need for additional study of the progression 126 of fibrosis during pregnancy. Currently, a multicenter, prospective observational cohort study is underway to evaluate 158 pregnancy outcomes of women with HCV; it is anticipated that this study will answer many of 159 the unresolved questions regarding HCV in pregnancy identified above. Outcomes being studied 160 include preterm delivery, gestational diabetes, preeclampsia, cholestasis, and infant birth weight other studies have failed to find such an association (9, 13). Importantly, these studies involved a 189 small number of vertically infected infants, ranging from 3 to 13. Because all published studies on mode of delivery and the risk of vertical transmission of HCV 379 are observational, and most did not assess viral load at the time of delivery, these results should 380 be interpreted cautiously (57). We recommend against cesarean delivery solely for the 381
indication of HCV (GRADE 1B). 382 383
Does labor management affect the risk of vertical transmission? 384
Several factors in labor management may be associated with an increased risk of vertical 385 transmission of HCV, namely prolonged rupture of membranes, internal fetal monitoring, and 386 episiotomy. One study reported that membrane rupture for >6 hours was associated with 387 increased risk of vertical transmission (28). Another study found that the median duration of 388 membrane rupture was significantly longer among women who transmitted HCV to their infantsM A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT than among those who did not (28 vs.16 hours) (58). Regarding invasive fetal monitoring, a 390
retrospective study including 710 HCV-infected women (59) and a prospective study including 391 242 HCV-infected women (28) both reported that internal fetal monitoring was associated with 392 increased risk of transmission compared with no internal monitoring. In contrast, a retrospective 393 study with 724 women found no association (60). One of these studies also found that 394 episiotomy was significantly associated with an increased risk of vertical transmission (59). 395
Based on the available evidence, we recommend that obstetric care providers avoid internal 396 fetal monitoring, prolonged rupture of membranes, and episiotomy in managing labor in 397 HCV-positive women (GRADE 1B), unless it is unavoidable in the course of management (i.e. 398 when unable to trace the fetal heart rate with Doppler and the alternative is proceeding with 399 cesarean delivery). We also recommend that obstetric care providers avoid early amniotomy and 400 Because anti-HCV antibodies can be transmitted across the placenta from a pregnant woman to 420 the fetus, the presence of anti-HCV antibodies in a neonate's serum soon after delivery is not 421 diagnostic of neonatal infection. In a prospective study of vertical transmission of HCV that 422 included 235 uninfected infants, anti-HCV antibodies were found in 96.8% of infants at birth, 423
15.3% at age 12 months, 1.6% at age 18 months, and 1.0% at age 24 months (28). This study 424 defined infants as HCV infected if they were positive for HCV RNA on at least two occasions at 425 age 1 month or older or if they were anti-HCV positive at 24 months of age or older (28). The 426 American Academy of Pediatrics and CDC recommend screening of infants born to HCV-427 positive women for anti-HCV antibodies after 18 months of age or for HCV RNA on two 428 occasions in infants older than 1 month of age (61). 
